tetraethylammonium has been researched along with apomorphine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Groves, PM; Sawyer, SF; Tepper, JM; Young, SJ | 1 |
| Daabees, TT; El-Din, MM; Senbel, AM; Sharabi, FM | 1 |
| Faraji, A; Fraidouni, N; Hadibeygi, E; Haghdoost-Yazdi, H; Movahedi, M; Vaezi, F | 1 |
| Alipour Heidari, M; Dargahi, T; Faraji, A; Fraidouni, N; Haghdoost-Yazdi, H; Mahmudi, M; Piri, H | 1 |
| Alipour Heidari, M; Dargahi, T; Faraji, A; Fraidouni, N; Haghdoost-Yazdi, H; Najafipour, R; Piri, H | 1 |
6 other study(ies) available for tetraethylammonium and apomorphine
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Autoreceptor-mediated changes in dopaminergic terminal excitability: effects of potassium channel blockers.
Topics: 4-Aminopyridine; Aminopyridines; Animals; Apomorphine; Corpus Striatum; Electric Stimulation; Ion Channels; Male; Neural Inhibition; Potassium; Rats; Rats, Inbred Strains; Receptors, Dopamine; Tetraethylammonium; Tetraethylammonium Compounds | 1986 |
Peripheral modulation of dopaminergic receptors affects erectile responses in rats.
Topics: Animals; Apomorphine; Benzazepines; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ejaculation; Electric Stimulation; Female; Heart Rate; Injections, Intravenous; Male; Penile Erection; Penis; Potassium Channel Blockers; Rats; Receptors, Dopamine D1; Sexual Behavior, Animal; Sulpiride; Tetraethylammonium; Time Factors | 2007 |
Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease.
Topics: 4-Aminopyridine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Drug Interactions; Male; Medial Forebrain Bundle; Microinjections; Oxidopamine; Parkinson Disease, Secondary; Potassium Channel Blockers; Rats; Rats, Wistar; Tetraethylammonium | 2011 |
Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation.
Topics: 4-Aminopyridine; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Functional Laterality; Male; Mental Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Postural Balance; Potassium Channel Blockers; Rats; Rats, Wistar; Tetraethylammonium; Thiazolidinediones | 2016 |
Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model.
Topics: 4-Aminopyridine; Animals; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Synergism; Male; Malondialdehyde; Medial Forebrain Bundle; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Potassium Channel Blockers; Rats; Rotarod Performance Test; Tetraethylammonium | 2017 |